Tumor suppressor CAR-1

Details Tumor suppressor CAR-1 Tumor suppressor CAR-1

2007-01-30

2007-01-30

Whiteman, Brian (Department: 1635)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

Reexamination Certificate

active

11153238

ABSTRACT:
The present invention relates to a new tumor suppressor, designated CAR-1, the gene for which is located on the short arm of human chromosome 1. This gene is directly implicated in colon, kidney and breast cancers, and the CAR-1 ubiquitous expression of the corresponding transcript suggests that it may be involved in yet others. Thus, one aspect of the invention is the diagnosis of CAR-1-related malignancies. The full length cDNA for CAR-1, as well as oligonucleotides derived therefrom, are disclosed. Screening methods for modulators of CAR-1 function and expression, as well as methods for cancer therapy, are described.

REFERENCES:
patent: 5872237 (1999-02-01), Feder et al.
patent: 5932210 (1999-08-01), Gregory et al.
patent: 6312926 (2001-11-01), Shatkin et al.
patent: 6551828 (2003-04-01), Clark
patent: 2002/0048763 (2002-04-01), Penn et al.
patent: 2002/0198371 (2002-12-01), Wang et al.
patent: 1 074 617 (2001-02-01), None
patent: WO 98/42739 (1998-10-01), None
patent: WO 01 57182 (2001-09-01), None
Anderson et al., Nature, vol. 392, pp. 25-30, 1998.
Verma, Nature, vol. 389, pp. 239-242, 1997.
Vile et al., Gene Therapy, vol. 7, pp. 2-8, 2000.
McNeish et al., Gene Therapy 2004, vol. 7, 1-7.
Attwood,Science, 290:471-473, 2000.
Avela et al., “Gene encoding a new RING-B-box-Coiled-coil protein is mutated in mulibrey nanism,”Nature Genetics, 25:298-301, 2000.
Baker et al.,Science, 294:93-96, 2001.
Bieche et al., “Deletion mapping in breast tumor cell lines point to two distinct tumor-suppressor genes in the 1p32-ter region, one of deleted regions (1p36.2) being located within the consensus region of LOH in neuroblastoma,”Oncology Reports, 5:167-172, 1998.
Bieche et al., “Two distinct regions involved in 1p deletion in human primary breast cancer,”Cancer Research, 53:1990-1994, 1993.
Borden, “RING domains: master builders of molecular scaffolds?”J. Mol. Biol., 295:1103-1112, 2000.
Borg et al., Chromosome 1 alterations in breast cancer: allelic loss on 1p and 1q is related to lymphogenic metastases and poor prognosis,Genes, Chromosomes, and Cancer, 5:311-320, 1992.
Couch et al., “Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene: Breast Cancer Information Care,”Human Mutation, 8:8-18, 1996.
Cox et al., “New mutations in MID 1 provide support for loss of function as the cause of X-linked Opitz syndrome,”Human Molecular Genetics, 9(17):2553-2562, 2000.
EMBL Database Accession No. AK001621, Feb. 22, 2000.
EMBL Database Accession No. BE258134, Jul. 14, 2000.
GenBank Accession No. AC022262.
GenBank Accession No. R71654.
Gerhold et al.,BioEssays, 18:973-981, 1996.
Han et al., “Infrequent somatic mutations of the p73 gene in various human cancers,”Euro. J. Surgical Oncology, 25:194-198, 1999.
Ichimiya et al., “p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent,”Oncogene, 18:1061-1066, 1999.
Isomura et al., “RFP is a DNA binding protein associated with the nuclear matrix,”Nucleic Acids Res., 20:5305-5310, 1992.
Kovacs et al., “Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma,”Proc. Nat'l Acad. Sci. USA, 85:1571-1575, 1988.
Le Douarin et al., “The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18,”EMBO J., 14:2020-2033, 1995.
Lee et al., “The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity,”Nature, 329:642-645, 1987.
Lo Cunsolo et al., “Neuroblastoma on two siblings supports the role of 1p36 deletion in tumor development,”Cancer, Genetics, &Cytogenetics, 109:126-130, 1999.
Loft et al., “Physical and functional mapping of a tumor suppressor locus for renal cell carcinoma within chromosome 3p12,”Cancer Research, 58: 3533-3537, 1998.
Lovell et al., The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment and VHL mutation,Cancer Research, 59: 2182-2189, 1999.
Matsuzaki et al., “Detailed deletion mapping on chromosome 1p32-p36 in human colorectal cancer: Identification of three distinct regions of common allelic loss,”Int. J. Oncology, 13:1229-1233, 1998.
McCluskey et al., “Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity,”Bioorganic&Medicinal Chemistry Letters, 10:1687-1690, 2000.
Miki et al., “A strong candidate for the breast and ovarian-cancer susceptibility gene BRCA1,”Science, 266:66-71, 1994.
Millikan et al., “Linkage analysis and loss of heterozygosity for chromosome Arm 1p in familial breast cancer,”Genes, Chromosomes, and Cancer, 25:354-361, 1999.
Ngo et al., “The protein folding problem and tertiary structure prediction,” Merz et al., ed., Birkhauswer, Boston, MA, pp. 433 and 492-495, 1994.
Ogunbiyi et al., “Prognostic value of chromosome 1p allelic loss in colon cancer,”Gastroenterology, 113:761-766, 1997.
Pandolfi, PML, PLZF, and NPM genes in the molecular pathogenesis of acute promyelocytic leukemia,Haematologica, 81:472-482, 1996.
Ragnarsson et al., “Loss of heterozygosity at chromosome ip in different solid human tumours: association with survival,”British J. of Cancer, 79:1468-1474, 1999.
Rasio et al., “Characterization of the human homologue of RAD54: a gene located on chromosome 1p32 at a region of high loss of heterozygousity in breast tumors,”Cancer Research, 57:2378-2383, 1997.
Russell et al.,J of Molecular Biology, 244:332-350, 1994.
Sambrook et al., Molecular Cloning, a Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, p. 11.47, 1989.
Sanchez et al., “A tumor suppressor locus within 3p14-p12 mediates rapid cell death of renal cell carcinomin vivo.,” Proc. Nat'l Acad. Sci., 91:3383-3387, 1994.
Saurin et al., “Does this have a familiar RING?”TIBS, 21:208-214, 1996.
Shimono et al., “RET finger protein is a transcriptional repressor and interacts with enhancer of polycomb that has dual transcriptional functions,”J. Biol. Chem., 275(50):39411-39419, 2000.
Somme et al., “Clonal karyotypic abnormalities in colorectal adenomas: clues to the early genetic events in the adenoma-carcinoma sequence,”Genes, Chromosomes and Cancer, 10:190-196, 1994.
Steck et al., “Identification of a candidate tumour suprressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers,”Nature Genetics, 15:356-362, 1997.
Szabo and King, “Inherited breast and ovarian cancer,”Human Molecular Genetics, 4:1811-1817, 1995.
Tanaka et al., “Suppresson of tumorigenicity in human colon carcinoma cells by introduction of normal chromosome 1p36 region,”Oncogene, 8:2253-2258, 1993.
Tsukamato et al., “Allelic loss on chromosome 1p is associated with progression and lymph node metastasis of primary breast carcinoma,”Cancer, 82:317-322, 1998.
Vogelstein, “Cancer. A deadly inheritance,”Nature. 348:681-682, 1990.
Wallace et al.,Methods Enzymol, 152:432-443, 1987.
Weinberg, “Positive and negative controls on cell growth,”Biochemistry, 28:8263-8269, 1989.
Wells et al.,J of Leukocyte Biology, 61:545-550, 1997.
Wu et al., “Identification of A RING protein that can interact in vivo with the BRCA1 gene product,”Nature Genetics, 14:430-440, 1996.

Affiliated with

Also associated with

Rating

Tumor suppressor CAR-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor suppressor CAR-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor suppressor CAR-1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3810431